BetterLife Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BETRF research report →
Price Chart
About the company
BetterLife Pharma Inc. , a biotechnology firm headquartered in Vancouver, Canada, specializes in researching and bringing to market therapeutic compounds designed to address neurological disorders across the globe. The company's core focus involves refining and advancing drug candidates derived from interferon-based technologies, which are intended to leverage the immune system to combat viral infections.
- CEO
- Ahmad Doroudian
- IPO
- 2010
- Employees
- 7
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on BETRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $30.76M
- P/E
- -12.27
- PEG
- 0.12
- P/S
- 0.00
- P/B
- -4.00
- EV/EBITDA
- -17.68
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 34.90%
- ROIC
- 49.78%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,811,448
- Net Income
- $-1,497,847+57.5%
- EPS
- $-0.01+64.1%
- OCF Growth
- +69.0%
- FCF Growth
- +69.0%
- 52W High
- $0.33
- 52W Low
- $0.03
- 50D MA
- $0.23
- 200D MA
- $0.10
- Beta
- 0.22
- RSI (14)
- 42
- Avg Volume
- 138.43K
No earnings-call transcripts are available for BETRF yet.
- Free Float
- 65.6%
- Shares Outstanding
- 161.89M
- Float Shares
- 106.26M
of shares held by institutions
1 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 24, 13 | Doroudian Ahmad | buy | 35,000,000 |
| Jan 31, 14 | Doroudian Ahmad | other | 0 |
| Jan 31, 14 | Doroudian Ahmad | other | 0 |
| Jan 31, 14 | Doroudian Ahmad | other | 0 |
| Jan 31, 14 | Doroudian Ahmad | other | 0 |
| Jan 31, 11 | Doroudian Ahmad | other | 0 |
| Jan 31, 11 | Doroudian Ahmad | other | 0 |
| Jan 31, 11 | Doroudian Ahmad | other | 0 |
| Jan 31, 11 | Doroudian Ahmad | other | 0 |
| May 25, 10 | Doroudian Ahmad | other | 800,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BETRF coverage
Recent articles, reports, and earnings notes.
No research on BETRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BETRF report →BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
newsfilecorp.com · Sep 29
BetterLife Pharma Inc. (OTCMKTS:BETRF) Sees Large Decrease in Short Interest
defenseworld.net · Sep 29
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
newsfilecorp.com · Aug 31
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
newsfilecorp.com · Aug 19
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
newsfilecorp.com · Jul 13
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
newsfilecorp.com · Jul 6
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
newsfilecorp.com · Jun 25
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
feeds.newsfilecorp.com · Jun 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.